Unfortunately, the few randomized clinical trials and observational and cohort studies that have evaluated the effect of IL-1β inhibition in relation to the development of post-MI cardiac remodeling have provided conflicting results [121,122,123,124] (Table 2). This evidence concerns the gene IL1B and myocardial infarction.